Please wait while the formulary information is being retrieved.
SYNDROS (DRONABINOL)
- Anorexia from HIV
- Cancer chemotherapy-induced nausea and vomiting
5 mg/mL oral solution
- 4.2 mg/m2 by oral route 1-3 hours prior to chemotherapy, then every 2-4 hrs after chemo as needed, for a total of 4-6 doses daily
Anorexia from HIV
- 0.42 milliliter (2.1 mg) by oral route 2 times per day
- 0.84 milliliter (4.2 mg) by oral route 2 times per day
- 1.68 milliliters (8.4 mg) by oral route 2 times per day
Cancer chemotherapy-induced nausea and vomiting
- 4.2 mg/m2 by oral route 1-3 hours prior to chemotherapy, then every 2-4 hrs after chemo as needed, for a total of 4-6 doses daily
- 12.6 mg/m2 by oral route 1-3 hours prior to chemotherapy, then every 2-4 hrs after chemo as needed, for a total of 4-6 doses daily
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Orthostatic hypotension
- Pregnancy
Severe
Moderate
- Alcoholism
- Bipolar disorder
- Depression
- Drug abuse
- Hypertension
- Hypotension
- Lower seizure threshold
- Schizophrenia
- Seizure disorder
- Tachyarrhythmia
SYNDROS (DRONABINOL)
- Anorexia from HIV
- Cancer chemotherapy-induced nausea and vomiting
- Acute confusion
- Hallucinations
- Mood changes
- Abdominal pain with cramps
- Concentration difficulty
- Disturbance in thinking
- Dizziness
- Drowsy
- Euphoria
- Nausea
- Unsteady gait
- Vomiting
More Frequent
Severe
Less Severe
- Memory impairment
- Palpitations
- Tachycardia
- Vasodilation of blood vessels
- Flushing
- General weakness
- Symptoms of anxiety
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Accidental fall
- Conjunctivitis
- Delirium
- Depersonalization
- Depression
- Drug-induced psychosis
- Dysarthria
- Fecal incontinence
- Hypertension
- Hypotension
- Panic disorder
- Seizure disorder
- Throat constriction
- Unconsciousness
Less Severe
- Altered mental status
- Anorexia
- Blurred vision
- Chills
- Cough
- Diarrhea
- Fatigue
- Headache disorder
- Hyperhidrosis
- Insomnia
- Involuntary muscle movement
- Lip swelling
- Malaise
- Myalgias
- Nervousness
- Nightmares
- Orthostatic hypotension
- Paranoid disorder
- Rhinitis
- Sinusitis
- Stinging of skin
- Syncope
- Tinnitus
- Urticaria
- Visual changes
- Xerostomia
Contraindicated
None
Severe Precaution
Dronabinol
Possible increased sensitivity to neurological and psychoactive adverse effects. No established safety and efficacy.
- 1 Day – 18 Years
- Possible increased sensitivity to neurological and psychoactive adverse effects. No established safety and efficacy.
Management or Monitoring Precaution
None
Dronabinol
- Severity Level:
D
- Additional Notes: Insufficient human data; animal data suggest dev tox
Contraindicated
Dronabinol
Use is not recommended; drug is concentrated in breast milk.
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Excreted | Drug shown to have adverse effect | Use is not recommended; drug is concentrated in breast milk. |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Dronabinol
General-Elderly may be more sensitive to the neuropsychiatric and postural hypotensive effects. Consider a lower starting dose. Neuro/Psych-Psychoactive effects including cognitive impairment and altered mental state, and possible drug-dependence requires close monitoring. Consider patient fall risk.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Anorexia from HIV | |
| R63.0 | Anorexia |
| Cancer chemotherapy-induced nausea and vomiting | |
| R11.2 | Nausea with vomiting, unspecified |
| Z51.11 | Encounter for antineoplastic chemotherapy |
| 0-9 | A-Z |
|---|---|
| R11.2 | Nausea with vomiting, unspecified |
| R63.0 | Anorexia |
| Z51.11 | Encounter for antineoplastic chemotherapy |
Formulary Reference Tool